Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C Pamela S. Belperio, Elizabeth W. Hwang, I. Chun Thomas, Larry A. Mole, Ramsey C. Cheung, Lisa I. Backus Clinical Gastroenterology and Hepatology Volume 11, Issue 8, Pages 1021-1027 (August 2013) DOI: 10.1016/j.cgh.2013.03.006 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Boceprevir and telaprevir on-treatment rates over time. Clinical Gastroenterology and Hepatology 2013 11, 1021-1027DOI: (10.1016/j.cgh.2013.03.006) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Futility and treatment discontinuation up to week 24 in patients treated with pegylated interferon/ribavirin and either boceprevir or telaprevir: (A) boceprevir, and (B) telaprevir. Clinical Gastroenterology and Hepatology 2013 11, 1021-1027DOI: (10.1016/j.cgh.2013.03.006) Copyright © 2013 AGA Institute Terms and Conditions